Brought to you by 
Janssen gets rights to Achillion's HCV assets; deal terminated
12 Sep 2017
Executive Summary
Achillion Pharmaceuticals Inc. licensed Janssen Pharmaceuticals Inc. exclusive worldwide rights to develop and commercialize hepatitis C compounds including ACH3102, ACH3422, and sovaprevir (ACH1625).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com